|
Compound class:
Antibody
Comment: Vantictumab (OMP-18R5) is an anti-FZD antagonistic monoclonal that induces inhibition of the Wnt signalling pathway [2]. It is being developed by OncoMed Pharmaceuticals. As receptors for Wnt ligands the FZD receptors are molecular targets for the prevention and treatment of cancer and inflammation that lie upstream of β‑catenin. Inhibition of Wnt-induced FZD activation by vantictumab reduces tumour cell proliferation and in vivo tumorigenicity [1], indicating the potential utility of blocking the activation of selected members of the FZD receptor family as a treatment for a wide range of tumours.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Bioactivity Comments |
| Vantictumab binds to 5 of the 10 human FZD receptors; FZD1, FZD2, FZD5, FZD7 and FZD8 [1]. The IC50 values provided in the table are estimates made from the binding curves produced in [1] and indicate the concentration of vantictumab that inhibits Wnt binding to each FZD receptor by 50%. |
| Selectivity at GPCRs | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
